Jin-Ju Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jin-Ju Lee has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Charles A. McWherter
CymaBay Therapeutics, Inc., Fremont, California, United States
1 shared publication- Christopher Pittman
University of South Florida Morsani College of Medicine, Tampa, FL; Vein911 Vein Treatment Centers, Tampa, FL
1 shared publication Esaan Azizi
University of South Florida Morsani College of Medicine, Tampa, FL
1 shared publicationJeff D. Johnson
CymaBay Therapeutics, Inc., Fremont, California, United States
1 shared publicationJiangao Song
CymaBay Therapeutics, Inc., Fremont, California, United States
1 shared publication- John Blebea
Central Michigan University College of Medicine
1 shared publication
Latest Publications
- Open Access
- 23 October 2025
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 14 (1) , 102347
General and disease-specific quality-of-life improvement following superficial venous insufficiency treatment
- 23 October 2025
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 14 (1) , 102347
Open AccessGeneral and disease-specific quality-of-life improvement following superficial venous insufficiency treatment
- Open Access
- 1 February 2024
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 326 (2) , G120-G132
Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis
NASH is a chronic, progressive, and increasingly problematic liver disease that has been resistant to treatment with individual therapeutics. In this study using a diet-induced mouse model of NASH, we found that the PPARδ agonist seladelpar reduced fibrosis and NASH pathology alone and in combinations with a GLP-1-R agonist (liraglutide) or an ASK1 inhibitor (selonsertib). Liver transcriptome analysis comparing each agent and coadministration suggests seladelpar should be effective in combination with a variety of therapeutics.
- 1 February 2024
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 326 (2) , G120-G132
Open AccessSeladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis
NASH is a chronic, progressive, and increasingly problematic liver disease that has been resistant to treatment with individual therapeutics. In this study using a diet-induced mouse model of NASH, we found that the PPARδ agonist seladelpar reduced fibrosis and NASH pathology alone and in combinations with a GLP-1-R agonist (liraglutide) or an ASK1 inhibitor (selonsertib). Liver transcriptome analysis comparing each agent and coadministration suggests seladelpar should be effective in combination with a variety of therapeutics.
- 1 August 2022
- Published by Academy of Management in Academy of Management Proceedings
- Vol. 2022 (1)
Cybershaming: Conceptualizing Organizational Shaming in the Digital Age
Recent years have seen a dramatic rise in the cases of Cybershaming of businesses. Social media has enhanced organizational transparency to actors both within and outside, consequently disrupting i...
- 1 August 2022
- Published by Academy of Management in Academy of Management Proceedings
- Vol. 2022 (1)
Cybershaming: Conceptualizing Organizational Shaming in the Digital Age
Recent years have seen a dramatic rise in the cases of Cybershaming of businesses. Social media has enhanced organizational transparency to actors both within and outside, consequently disrupting i...